A Phase 1/1b Study of IAM1363 in HER2 Cancers
Phase 1
243
about 4 years
18+
29 sites in CA, CO, FL +15
What this study is about
Researchers are testing a treatment called IAM1363 to see if it's safe and effective for people with advanced cancers that have HER2 changes. The trial will involve adults, and the estimated length of it is 1467 days.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take IAM1363
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Confirmed central nervous system ORR (CNS-cORR), Confirmed objective response rate (cORR), Incidence and severity of adverse events (AEs), Pharmacokinetic (PK) parameters
Secondary: Best overall response (BoR) rate, Clinical benefit rate (CBR), Disease control rate (DCR), Duration of response (DoR), Overall survival (OS), Progression-free survival (PFS)
Oncology, Neurology